Compare VTIX & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTIX | GANX |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.9M | 88.6M |
| IPO Year | 2025 | 2021 |
| Metric | VTIX | GANX |
|---|---|---|
| Price | $1.33 | $2.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | ★ 773.3K | 490.8K |
| Earning Date | 08-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.99 | 31.46 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,252,643.00 | $55,180.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 18.44 | N/A |
| 52 Week Low | $1.42 | $1.53 |
| 52 Week High | $9.00 | $4.34 |
| Indicator | VTIX | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 28.35 | 55.28 |
| Support Level | N/A | $1.64 |
| Resistance Level | $2.03 | $2.05 |
| Average True Range (ATR) | 0.19 | 0.13 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 6.67 | 47.18 |
Virtuix Holdings Inc pioneers movement in AI-generated worlds, both imaginary and real. The company is the creator of Omni, a brand of omni-directional treadmills that enable users to walk and run in 360 degrees inside virtual reality (VR) games, digital twins, and other applications. Its technology operates at the intersection of gaming, fitness, and enterprise VR. Its products include Omni Pro, Omni Arena, and Omni One. Its business integrates a consumer and enterprise VR hardware platform anchored by its flagship Omni One product with a defense-oriented simulation system, Virtual Terrain Walk (VTW), targeting next-generation immersive mission planning.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.